Prognosis in myelodysplastic syndromes: Are the new classifications useful?

被引：0

作者：

Galili N. ^{[1
]}

Raza A. ^{[1
]}

机构：

[1] St. Vincent's Comprehensive Cancer Center, New York, NY 10011

来源：

Current Hematologic Malignancy Reports | 2008年 / 3卷 / 1期

关键词：

Acute Myeloid Leukemia; Myelodysplastic Syndrome; Refractory Anemia; International Prognostic Scoring System; Bone Marrow Blast;

D O I：

10.1007/s11899-008-0004-z

中图分类号：

学科分类号：

摘要：

Increased understanding of the biologic and clinical parameters that define subgroups of myelodysplastic syndromes has led to continuing refinement of classification strategies for diagnostic and prognostic use. The French-American-British classification, based primarily on morphology, was modified by the World Health Organization system to include the negative impact of multilineage dysplasias and higher blast counts. In addition, this system identifies a distinct clinical subgroup characterized by an isolated chromosome 5 deletion. The International Prognostic Scoring System was created to calculate prognosis, risk of transformation to acute myeloid leukemia, and median survival times. However, therapeutic decisions cannot be solely guided by these systems, and the clinician must decide whether the intent is curative or palliative. Clinical symptoms and degree of transfusion dependency will dictate the degree of therapeutic intervention. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：19 / 22

页数：3

共 20 条

[1]

Block M., Jacobson L.O., Bethard W.F., Preleukemic acute human leukemia, J Am Med Assoc, 152, pp. 1018-1028, (1953)

[2]

Bennett J.M., Catovsky D., Daniel M.T., Et al., Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol, 33, pp. 451-458, (1976)

[3]

Bennett J.M., Catovsky D., Daniel M.T., Et al., Proposals for the classification of the myelodysplastic syndromes, Br J Haematol, 51, pp. 189-199, (1982)

[4]

Mufti G.J., Stevens J.R., Oscier D.G., Et al., Myelodysplastic syndromes: A scoring system with prognostic significance, Br J Haematol, 59, pp. 425-433, (1985)

[5]

Sanz G.F., Sanz M.A., Vallespi T., Et al., Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients, Blood, 74, pp. 395-408, (1989)

[6]

Morel P., Hebbar M., Lai J.L., Et al., Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases, Leukemia, 7, pp. 1315-1323, (1993)

[7]

Aul C., Gattermann N., Heyll A., Et al., Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposal for an improved scoring system, Leukemia, 6, pp. 52-59, (1992)

[8]

Greenberg P., Cox C., LeBeau M.M., Et al., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, pp. 2079-2088, (1997)

[9]

Germing U., Gattermann N., Minning H., Et al., Problems in the classification of CMML - dysplastic versus proliferative type, Leuk Res, 22, pp. 871-878, (1998)

[10]

Vardiman J.W., Harris N.L., Brunning R.D., The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, pp. 2292-2302, (2002)

← 1 2 →